Association of T-Cell Receptor Repertoire Use With Response to Combined Trastuzumab-Lapatinib Treatment of HER2-Positive Breast Cancer

Authors:

Abstract
The Neoadjuvant Lapatinib and/or Trastuzumab Treatment Optimisation (NeoALTTO) trial demonstrated that trastuzumab, a monoclonal antibody against HER2, and lapatinib, a small-molecule tyrosine kinase inhibitor of the EGFR and HER2 family, administered together with paclitaxel chemotherapy in the neoadjuvant setting increased rates of pathologic complete response (pCR) by approximately 20% in patients with early-stage HER2-positive breast cancer compared with either treatment alone.1 A higher tumor-associated lymphocyte count2 and a higher expression of immune signatures3 were associated with higher rates of pCR but not with specific benefit from dual treatments. In this study, we examine whether specific T-cell receptor (TCR) species could indicate an association with response to a specific treatment arm.